WEREWOLF THERAPEUTICS, INC. Interest Expense Nonoperating
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Interest Expense Nonoperating of $475.00 thousand for the 3-month period ending 2026-06-30, per its S-4 filed 2026-09-22.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $475.00K, a 63.49% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $1.37M, a 8.31% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $1.37M, a 8.05% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $1.34M, a 7.80% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. interest expense nonoperating for fiscal 2023 was $3.14M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $475.00K S-4 · filed 2026-09-22 | $1.84M S-4 · filed 2026-09-22 | $3.21M derived: sum of 3 quarters · filed 2026-09-22 | $4.55M derived: sum of 4 quarters · filed 2026-09-22 |
| 2026-03-31 | $1.37M 10-Q · filed 2026-05-07 | $2.74M derived: sum of 2 quarters · filed 2026-09-22 | $4.08M derived: sum of 3 quarters · filed 2026-09-22 | $5.38M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-12-31 | $1.37M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $2.71M derived: sum of 2 quarters · filed 2026-09-22 | $4.01M derived: sum of 3 quarters · filed 2026-09-22 | $5.27M S-4 · filed 2026-09-22 |
| 2025-09-30 | $1.34M 10-Q · filed 2025-11-04 | $2.64M derived: sum of 2 quarters · filed 2026-09-22 | $3.90M 10-Q · filed 2025-11-04 | $5.17M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-06-30 | $1.30M S-4 · filed 2026-09-22 | $2.56M S-4 · filed 2026-09-22 | $3.83M derived: sum of 3 quarters · filed 2026-09-22 | $5.08M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-03-31 | $1.26M 10-Q · filed 2026-05-07 | $2.53M derived: sum of 2 quarters · filed 2026-09-22 | $3.77M derived: sum of 3 quarters · filed 2026-09-22 | $4.92M derived: sum of 4 quarters · filed 2026-09-22 |
| 2024-12-31 | $1.27M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $2.51M derived: sum of 2 quarters · filed 2026-09-22 | $3.65M derived: sum of 3 quarters · filed 2026-09-22 | $4.66M S-4 · filed 2026-09-22 |
| 2024-09-30 | $1.24M 10-Q · filed 2025-11-04 | $2.39M derived: sum of 2 quarters · filed 2025-11-04 | $3.39M 10-Q · filed 2025-11-04 | $4.40M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $1.14M 10-Q · filed 2025-08-14 | $2.15M 10-Q · filed 2025-08-14 | $3.15M derived: sum of 3 quarters · filed 2025-08-14 | $4.16M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.00M 10-Q · filed 2025-05-08 | $2.01M derived: sum of 2 quarters · filed 2025-05-08 | $3.02M derived: sum of 3 quarters · filed 2025-05-08 | $3.97M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $2.01M derived: sum of 2 quarters · filed 2025-03-11 | $2.97M derived: sum of 3 quarters · filed 2025-03-11 | $3.14M 10-K · filed 2025-03-11 |
| 2023-09-30 | $1.00M 10-Q · filed 2024-11-07 | $1.96M derived: sum of 2 quarters · filed 2024-11-07 | $2.13M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $955.00K 10-Q · filed 2024-08-08 | $1.13M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |